A new study published in Nature: Scientific reports observed significant mood and mental health benefits after one month of microdosing psilocybin mushrooms.
Mushroom microdosers showed greater improvements in the DASS domains depression, Anxietyand stress. The study showed that they found no difference in these results between genders, but found that the cognitive efficacy of the microdose was more effective in people under the age of 55.
The study looked at 1,133 people over two years. All subjects were over 18 years of age, could read English, and had access to an iPhone iOS device where participants recorded their scores. Scientific reports is a peer-reviewed open access scientific journal published online by Natural portfolio.
The study was conducted by a team of experts in psychology and mycology: Joseph M. Rutman, Department of Psychology, University of British Columbia, Kelowna, British Columbia, Canada; Maggie Kiraga, employee of Quantified Citizen Technologies. Pamela Kriskow, Clinical Advisory Board Member of Numinus Wellness, Co-Founder of MycoMedica Life Sciences and on the Scientific and Medical Advisory Board; Kalyn Harvey; Paul Stamets, who founded Fungi Perfecti, LLC; Eesmyal Santos-Brault; Kim PC Kuypers; and Zach Walsh, Advisory Board Member of the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada and MycoMedica Life Sciences.
“This research is an extension of our earlier manuscript published in the same journal, and we have additional publications in preparation that build on this same research,” says University of British Columbia Department of Psychology researcher Joseph Rutman. He says the team plans to continue this line of research and expand on these findings in the future. “Our team is also working hard to develop the next version of the study, which will be used to generate psychedelic microdosing discoveries for years to come.”
There isn’t one specific type of fungus or strain that the study used because it’s “observational in nature,” Rutman says. The researchers did not provide any psilocybin mushrooms to the participants, but observed and recorded the participants’ experiences as they engaged in their own “microdose practice.”
“In this initial version of the study, we did not ask participants specifically what variety of mushroom they used. Although we collected data on a practice called arrangement where psilocybin mushrooms are combined with other non-psychedelic substances, such as lion’s mane mushrooms or chocolate,” says Rutman. “Our first study noted that about half of the microdosers in our sample doped with a wide variety of substances, while our more recent study extended these findings by noting associated improvements in psychomotor abilities among doping microdosers compared to non-doping or non-microdosing peers. “
So, exactly how much is considered a microdose of psilocybin? The team seemed to have a precedent. “Based on previous psilocybin microdosing studies, we categorized participants’ psilocybin dose responses into low, medium, and high microdoses corresponding to ≤ 0.1 grams of dried mushrooms, 0.1–0.3 grams of dried mushrooms, respectively. ≥ 0.3 grams of dried mushrooms,” says Rutman. Most participants landed somewhere in the middle range of 0.1 to 0.3 grams of psilocybin. “We found that about 10% of our microdosing sample in this study reported high doses, 72.6% reported medium doses, and 16.8% reported low doses.”
These findings join the ranks of many peer-reviewed, legitimate academic studies that consider psilocybin as a reliable treatment for depression. The Journal of Psychopharmacology published earlier this year a follow-up to that widespread study from Johns Hopkins Medicine, which found that psilocybin could continue to help people with depression up to a year later.